Interpretation of Incidence Rates Data
Incidence Rate Report for Puerto Rico
Explanation of Column Headers
Non-Hodgkin Lymphoma (All Stages^), 2015-2019
All Races (includes Hispanic), Both Sexes, All Ages
Sorted by CI*Rank
Objective - The objective of *** is from the Healthy People 2020 project done by the Centers for Disease Control and Prevention.Incidence Rate (95% Confidence Interval) - The incidence rate is based upon 100,000 people and is an annual rate (or average annual rate) based on the time period indicated. Rates are age-adjusted by 5-year age groups to the 2000 U.S. standard million population.
Recent Trends - This is an interpretation of the AAPC/APC:
- Rising when 95% confidence interval of AAPC/APC is above 0.
- Stable when 95% confidence interval of AAPC/APC includes 0.
- Falling when 95% confidence interval of AAPC/APC is below 0.
AAPC/APC (95% Confidence Interval) - the change in rate over time
- Average Annual Percent Change - AAPCs are based upon APCs that were calculated by Joinpoint Regression Program
- Annual Percent Change - APCs calculated in SEER*Stat.
- Larger confidence intervals indicate less stability of the data. This is often due to low counts that are not quite low enough to be suppressed.
- Data is currently being suppressed if there are fewer than 16 counts for the time period.
Line by Line Interpretation of the Report
- Rate : The incidence rate is 14.6 with a 95% confidence interval from 14.1 to 15.2 and 576 average annual cases over 2015-2019.
- CI*Rank⋔ : N/A
- Recent Trend : The trend is stable because the trend is -1.2 with a 95% confidence interval from -5.4 to 3.2.
- Rate : The incidence rate is 19.0 with a 95% confidence interval from 18.9 to 19.0 and 71,841 average annual cases over 2015-2019.
- CI*Rank⋔ : N/A
- Recent Trend : The trend is falling because the trend is -1.8 with a 95% confidence interval from -2.4 to -1.3.
Created by statecancerprofiles.cancer.gov on 03/24/2023 8:36 am.
State Cancer Registries may provide more current or more local data.
⋔ Results presented with the CI*Rank statistics help show the usefulness of ranks. For example, ranks for relatively rare diseases or less populated areas may be essentially meaningless because of their large variability, but ranks for more common diseases in densely populated regions can be very useful. More information about methodology can be found on the CI*Rank website.
† Incidence rates (cases per 100,000 population per year) are age-adjusted to the 2000 US standard population (19 age groups: <1, 1-4, 5-9, ... , 80-84, 85+). Rates are for invasive cancer only (except for bladder cancer which is invasive and in situ) or unless otherwise specified. Rates calculated using SEER*Stat. Population counts for denominators are based on Census populations as modified by NCI. The US Population Data File is used for SEER and NPCR incidence rates.
Rates and trends are computed using different standards for malignancy. For more information see malignant.html.
^ All Stages refers to any stage in the Surveillance, Epidemiology, and End Results (SEER) summary stage.
Source: SEER and NPCR data. For more specific information please see the table.
Interpret Rankings provides insight into interpreting cancer incidence statistics. When the population size for a denominator is small, the rates may be unstable. A rate is unstable when a small change in the numerator (e.g., only one or two additional cases) has a dramatic effect on the calculated rate.
Data for the United States does not include data from Nevada.
Data for the United States does not include Puerto Rico.
When displaying county information, the CI*Rank for the state is not shown because it's not comparable. To see the state CI*Rank please view the statistics at the US By State level.